21
88
14
↑21
↓88
—14
Evidence suggests Melatonin maydecreasePain.
81 studies (123 claims)
Moderate consensus
Typical effective dose 6 (4.5–10.5) mgacross 24 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| preoperative oral melatonin medication | Decreases - were significantly lower | pain scores | Human | patients undergoing elective prostatectomy | 6 mg melatonin the night before and 1 hour before surgery. | Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial.cited 61× |
| preoperative oral melatonin medication | Decreases - was significantly lower | postoperative VAS of pain | Human | patients undergoing elective prostatectomy | 6 mg melatonin the night before and 1 hour before surgery. | Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial.cited 61× |
| melatonin 10 mg per day | Decreases - Significant improvements | pain | Human | the patient | 10 mg per day | Short-Lasting Unilateral Neuralgiform Headache with Conjunctival Injection and Tearing Secondary to Head and Neck Trauma: Literature Review and Case Report.cited 5× |
| melatonin 6 mg daily | Decreases - a significant improvement was observed | frequency of abdominal pain | Human | IBS patients with and without sleep disorders | 6 mg daily (3 mg fasting and 3 mg at bedtime). | The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study.cited 5× |
| melatonin 6 mg daily | Decreases - a significant improvement was observed | severity of abdominal pain | Human | IBS patients with and without sleep disorders | 6 mg daily (3 mg fasting and 3 mg at bedtime). | The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study.cited 5× |
| exogenous melatonin supplement | Decreases - was associated with significantly better improvement | IBS pain severity | Human | IBS patients | — | The efficacy of exogenous melatonin supplement in ameliorating irritable bowel syndrome severity: A meta-analysis of randomized controlled trials.cited 6× |
| melatonin at all three different doses (3, 5, 10 mg) | Decreases - postoperative pain was significantly less than the placebo group | postoperative pain | Human | patients undergoing an elective mini-open microdiscectomy surgery | — | The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial.cited 6× |
| melatonin at three different doses (3, 5, 10 mg) | No effect - no statistically significant differences in postoperative pain level between the three groups | postoperative pain level | Human | patients undergoing an elective mini-open microdiscectomy surgery | — | The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial.cited 6× |
| melatonin at a dose of 5 mg | Decreases - statistically significant differences between the two groups receiving melatonin at a dose of 5 mg and the placebo group | postoperative pain intensity | Human | patients undergoing an elective mini-open microdiscectomy surgery | — | The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial.cited 6× |
| preoperative oral melatonin | Decreases - postoperative pain was significantly less than the placebo group | postoperative pain | Human | patients undergoing an elective mini-open microdiscectomy surgery | — | The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial.cited 6× |
| oral melatonin with a dose of 5 mg, 1 hour before the surgery | Decreases - can effectively reduce pain intensity | pain intensity | Human | patients after lumbar laminectomy and discectomy | — | The Effect of Preoperative Oral Melatonin on Postoperative Pain after Lumbar Disc Surgery: A Double-Blinded Randomized Clinical Trial.cited 6× |
| melatonin (20 mg) along with conventional treatment | Decreases - aided in decreasing pain | pain scores | Human | head and neck cancer patients undergoing radiotherapy | 20 mg melatonin (frequency not specified). | Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial.cited 44× |
| melatonin 20 mg | No effect - found to be nonsignificant | ESAS pain | Human | patients with breast cancer undergoing RT | 20 mg orally, starting the night before radiotherapy initiation until 2 weeks post-radiotherapy. | Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.cited 6× |
| Melatonin | Decreases - showed improvement in | abdominal pain | Human | IBS patients | 3 mg at bedtime | Melatonin for the treatment of irritable bowel syndrome.cited 46× |
| melatonin | Decreases - reduction in | anxiety and pain | Human | — | Not specified | Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies.cited 147× |
| repeated administration of melatonin | Decreases - leads to lower levels of | pain | Human | — | Not specified | Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies.cited 147× |
| Melatonin (MLT) | Decreases - displays analgesic properties | chronic, acute, inflammatory and neuropathic pain | Human | animal paradigms | Not specified. | Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. |
| Melatonin (MLT) | Decreases - displays analgesic properties | chronic, acute, inflammatory and neuropathic pain | Human | animal paradigms | Not specified. | Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. |
| Melatonin | Decreases - conditionally recommended as benefits outweighed risks | chronic musculoskeletal pain | Human | Special Operations Forces personnel | Not specified | Dietary Ingredients as an Alternative Approach for Mitigating Chronic Musculoskeletal Pain: Evidence-Based Recommendations for Practice and Research in the Military. |
| Melatonin | Decreases - conditionally recommended as benefits outweighed risks | chronic musculoskeletal pain | Human | Special Operations Forces personnel | Not specified | Dietary Ingredients as an Alternative Approach for Mitigating Chronic Musculoskeletal Pain: Evidence-Based Recommendations for Practice and Research in the Military. |
| Melatonin | Decreases - application as a neuroprotective agent to control | cognitive deterioration ("brain fog") and pain in the ME/CFS syndrome-like documented in long COVID | Human | long COVID patients | — | Possible Application of Melatonin in Long COVID.cited 19× |
| melatonin | Decreases - reduced | daily pain scores | Human | Forty females, aged 18 to 45 years | 10 mg melatonin daily. | Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial.cited 98× |
| melatonin | Decreases - reduced | evoked pain | Animal | female neuropathic mice | — | Activation of spinal melatonin MT |
| melatonin | Decreases - reduced | evoked pain | Animal | male neuropathic mice | — | Activation of spinal melatonin MT |
| melatonin | Decreases - reduced | spontaneous pain | Animal | female neuropathic mice | — | Activation of spinal melatonin MT |
| melatonin | Decreases - reduced | spontaneous pain | Animal | male neuropathic mice | — | Activation of spinal melatonin MT |
| melatonin (MT) | Increases - could increase | heat pain latency | Animal | PHN Wistar rats | — | Analgesic effects of melatonin on post-herpetic neuralgia. |
| melatonin | Decreases - less well-evidenced current option | IBS pain | Human | patients with IBS | Not specified | Review article: current and future treatment approaches for pain in IBS.cited 27× |
| melatonin | Decreases - may provide analgesia | inflammatory-associated pain | Human | neonates and children before venepuncture | Not specified | Melatonin for anaesthetic indications in paediatric patients: a systematic review.cited 10× |
| melatonin | Decreases - had decreased | intensity of visceral pain and abdominal bloating | Human | IBS-C group | 3 mg fasting and 5 mg at bedtime. | Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women.cited 31× |
| Melatonin | Increases - significantly increased | mechanical and thermal pain thresholds | Animal | rat LDH model | — | The Effect of Melatonin on Radicular Pain in a Rat Model of Lumbar Disc Herniation. |
| Melatonin | Decreases - alleviates | radicular pain from LDH | Animal | rat LDH model | — | The Effect of Melatonin on Radicular Pain in a Rat Model of Lumbar Disc Herniation. |
| melatonin | Decreases - desirable effects outweighed undesirable effects | musculoskeletal pain | Human | Special Operations Forces personnel | Not specified | Conditional Recommendations for Specific Dietary Ingredients as an Approach to Chronic Musculoskeletal Pain: Evidence-Based Decision Aid for Health Care Providers, Participants, and Policy Makers.cited 13× |
| melatonin (MLT) | Decreases - has analgesic properties | neuropathic pain | Animal | preclinical studies | — | Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. |
| melatonin | Decreases - have shown promising results | neuropathic pain behaviors | Animal | rodent models | — | Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy. |
| melatonin | Decreases - possible action | orofacial pain | Human | — | Not provided | Involvement of Oxidative Stress and Nutrition in the Anatomy of Orofacial Pain.cited 5× |
| melatonin | Decreases - has analgesic effects | pain | Human | clinical studies undertaken during surgery | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - has analgesic effects | pain | Human | clinical studies undertaken during surgery | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - exerts antinociceptive and antiallodynic effects | pain perception | Human | animal models | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - exerts antinociceptive and antiallodynic effects | pain perception | Human | animal models | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - modulates pain perception | pain perception | Human | — | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - modulates pain perception | pain perception | Human | — | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - exerts its antinociceptive effects | pain perception | Human | — | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - exerts its antinociceptive effects | pain perception | Human | — | Not specified | Melatonin and its agonists in pain modulation and its clinical application. |
| melatonin | Decreases - indicate significant analgesic effects | pain | Human | humans | Not specified in the abstract. | The analgesic effects of exogenous melatonin in humans.cited 13× |
| exogenous melatonin | Decreases - demonstrate significant dose-dependent anti-nociceptive effects | pain | Human | experimental animals | Not specified in the abstract. | The analgesic effects of exogenous melatonin in humans.cited 13× |
| exogenous melatonin | No effect - No significant effects | pain during the burn injury and areas of secondary hyperalgesia | Human | human participants in a burn model | Not specified in the abstract. | The analgesic effects of exogenous melatonin in humans.cited 13× |
| perioperative melatonin | Decreases - demonstrated significant analgesic and anxiolytic effects | pain and anxiety | Human | surgical patients | Not specified in the abstract. | The analgesic effects of exogenous melatonin in humans.cited 13× |
| melatonin | Decreases - decreased | pain | Human | women with primary dysmenorrhea | Not specified | Both melatonin and meloxicam improved sleep and pain in females with primary dysmenorrhea-results from a double-blind cross-over intervention pilot study.cited 9× |
| melatonin | Increases - superior efficacy | treatment of pain and PD-related sleep complaints | Human | women with primary dysmenorrhea | Not specified | Both melatonin and meloxicam improved sleep and pain in females with primary dysmenorrhea-results from a double-blind cross-over intervention pilot study.cited 9× |
| melatonin | Decreases - has pain-killing properties | pain | Human | — | Not specified | Melatonin and morphine: potential beneficial effects of co-use.cited 31× |
| melatonin (MLT) | No effect - had no significant effect on | pain | Human | patients with cancer | — | Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials.cited 10× |
| melatonin (3 mg of melatonin into 2 ml of 2% hydroxyethyl cellulose gel packed into the socket) | Decreases - statistically significant improvement | pain | Human | patients who required removal of the impacted mandibular third molar | — | The Effect of Local Melatonin Application Following the Removal of an Impacted Mandibular Third Molar.cited 5× |
| Melatonin (MLT) | Decreases - recent studies suggest analgesic effects | pain | HumanAnimal | — | — | Melatonin Induces Analgesic Effects through MT |
| melatonin | Decreases - relieves | pain | Animal | — | — | Melatonin impedes Tet1-dependent mGluR5 promoter demethylation to relieve pain. |
| intrathecal melatonin injection | Decreases - reversed | the protein expression, protein-promoter coupling, promoter demethylation, and pain hypersensitivity induced by Tet1 gene transfer, spinal nerve ligation, and intraplantar complete Freund's adjuvant injection | Animal | rats | — | Melatonin impedes Tet1-dependent mGluR5 promoter demethylation to relieve pain. |
| melatonin | No effect - was not superior to placebo in reducing | pain associated with burning mouth syndrome | Human | BMS patients | 12 mg/day | Melatonin Treatment in Patients with Burning Mouth Syndrome: A Triple-Blind, Placebo-Controlled, Crossover Randomized Clinical Trial.cited 18× |
| melatonin | Decreases - low evidence for effectiveness | pain intensity | Human | participants with burning mouth syndrome | Not specified | WWOM VII: Effectiveness of systemic pharmacotherapeutic interventions in the management of BMS: A systematic review and meta-analysis.cited 13× |
| melatonin | Increases - proved to be statistically, although not clinically significant | pain measured with numeric rating scale (NRS) | Human | participants with severe dysmenorrhea | 10 mg daily at bedtime during the menstrual week. | Adjuvant use of melatonin for pain management in dysmenorrhea - a randomized double-blinded, placebo-controlled trial.cited 11× |
| 10 mg melatonin daily | Decreases - has previously been shown to reduce | level of pelvic pain | Human | women with endometriosis | 10 mg daily at bedtime during the menstrual week. | Adjuvant use of melatonin for pain management in dysmenorrhea - a randomized double-blinded, placebo-controlled trial.cited 11× |
| melatonin | Decreases - reduced more than did placebo | pain-related sleep interference scores | Human | type 2 diabetic patients suffering from painful diabetic neuropathy (PDN) | 3 mg/day for 1 week, then 6 mg/day for 7 weeks. | Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial.cited 13× |
| exogenous melatonin as an adjuvant to pregabalin | Decreases - resulted in a considerably higher reduction | mean NRS pain score | Human | type 2 diabetic patients suffering from painful diabetic neuropathy (PDN) | 3 mg/day for 1 week, then 6 mg/day for 7 weeks. | Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial.cited 13× |
| melatonin (5mg) | Decreases - reduced | pain scores | Human | females, aged 20-40 years, with myofascial TMD pain | 5mg daily. | Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study.cited 49× |
| melatonin (5mg) | Increases - increased | pressure pain threshold | Human | females, aged 20-40 years, with myofascial TMD pain | 5mg daily. | Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study.cited 49× |
| melatonin | Increases - caused the increase | pain threshold of the mechanical allodynia | Animal | rats with CCI | — | Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. |
| melatonin | No effect - no significant effect | postoperative pain | Human | patients | Not specified | Perioperative Pharmacological Sleep-Promotion and Pain Control: A Systematic Review.cited 20× |
| melatonin | Decreases - reduced | postoperative pain scores | Human | patients | Not specified | Perioperative Pharmacological Sleep-Promotion and Pain Control: A Systematic Review.cited 20× |
| melatonin | Increases - had higher VAS scores | postoperative pain | Human | patients aged 40-60 years old with American Society of Anesthesiologists physical status I-II undergoing laminectomy | — | Comparison of the effect of melatonin, dexmedetomidine, and gabapentin on reduction of postoperative pain and anxiety following laminectomy: a randomized clinical trial.cited 6× |
| melatonin | No effect - lacks robust clinical evidence | postoperative pain | Human | patients submitted to joint arthroplasty | Not specified | Perioperative Use of Melatonin in Joint Arthroplasty: A Critical Systematic Review of Randomized Clinical Studies. |
| perioperative melatonin administration | Decreases - found variable degrees of success | postoperative pain | Human | patients submitted to joint arthroplasty | Not specified | Perioperative Use of Melatonin in Joint Arthroplasty: A Critical Systematic Review of Randomized Clinical Studies. |
| melatonin | No effect - possible mechanism contributing to the sleep-pain relationship | sleep-pain relationship | Human | adult and pediatric populations | Not specified | Sleep and pain: recent insights, mechanisms, and future directions in the investigation of this relationship.cited 133× |
| melatonin | Decreases - had potent analgesic and anti-inflammatory effects | SNL-induced neuropathic pain | Animal | rats | — | The anti-inflammatory and analgesic effects of intraperitoneal melatonin after spinal nerve ligation are mediated by inhibition of the NF-κB/NLRP3 inflammasome signaling pathway. |
| melatonin | Decreases - significantly reduce | subjective pain perception | Human | orthognathic patients | Not specified | The effects of melatonin prophylaxis on sensory recovery and postoperative pain following orthognathic surgery: a triple-blind randomized controlled trial and biochemical analysis.cited 11× |
| prophylactic administration of melatonin | Decreases - confers significant clinical benefits | postoperative pain | Human | — | Not specified | The effects of melatonin prophylaxis on sensory recovery and postoperative pain following orthognathic surgery: a triple-blind randomized controlled trial and biochemical analysis.cited 11× |
| melatonin | Decreases - significantly reduced | subjective pain perception | Human | ZMC fracture patients | Not specified | Effects of melatonin on postoperative pain and sensory recovery following zygomaticomaxillary complex fractures - A randomized controlled trial.cited 1× |
| prophylactic administration of melatonin | Decreases - confers significant clinical benefits in terms of reduced postoperative pain and improved sensory recovery | postoperative pain and sensory recovery | Human | ZMC fracture patients | Not specified | Effects of melatonin on postoperative pain and sensory recovery following zygomaticomaxillary complex fractures - A randomized controlled trial.cited 1× |
| melatonin | Increases - increased | the inhibitory endogenous pain-modulating system as assessed by the reduction on NPS(0-10) during the CPM-TASK | Human | sixty-three females, aged 18 to 65 | 10 mg melatonin at bedtime, alone or with 25 mg amitriptyline. | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.cited 75× |
| melatonin in combination with amitriptyline | Increases - increased | the inhibitory PMS as assessed by the Numerical Pain Scale [NPS(0-10)] reduction during the CPM-TASK | Human | sixty-three females, aged 18 to 65 | 10 mg melatonin at bedtime, alone or with 25 mg amitriptyline. | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.cited 75× |
| melatonin alone | Increases - increased | the inhibitory PMS as assessed by the Numerical Pain Scale [NPS(0-10)] reduction during the CPM-TASK | Human | sixty-three females, aged 18 to 65 | 10 mg melatonin at bedtime, alone or with 25 mg amitriptyline. | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.cited 75× |
| melatonin alone or associated with amitriptyline | Decreases - was better than amitriptyline alone in improving | pain on the VAS | Human | sixty-three females, aged 18 to 65 | 10 mg melatonin at bedtime, alone or with 25 mg amitriptyline. | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.cited 75× |
| melatonin alone or in combination with amitriptyline | Decreases - reduced significantly | pain on the VAS | Human | sixty-three females, aged 18 to 65 | 10 mg melatonin at bedtime, alone or with 25 mg amitriptyline. | Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial.cited 75× |
| melatonin | No effect - has a role in | trigeminal pain processing | Human | — | — | Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.cited 25× |
| exogenous melatonin | Decreases - significant benefits of | abdominal pain | Human | IBS patients | Not specified | Implications of melatonin therapy in irritable bowel syndrome: a systematic review.cited 49× |
| preoperative oral administration of 6 mg melatonin | Decreases - were found significantly lower | mean pain score | Human | adult patients undergoing elective major abdominal surgery | 6 mg melatonin, single dose administered one hour before surgery. | Comparison of the effects of preoperative melatonin or vitamin C administration on postoperative analgesia.cited 19× |
| preoperative oral administration of 6 mg melatonin | No effect - no significant differences | pain scores | Human | adult patients undergoing elective major abdominal surgery | 6 mg melatonin, single dose administered one hour before surgery. | Comparison of the effects of preoperative melatonin or vitamin C administration on postoperative analgesia.cited 19× |
| preoperative oral administration of 6 mg melatonin | Decreases - led to a reduction | pain scores | Human | adult patients undergoing elective major abdominal surgery | 6 mg melatonin, single dose administered one hour before surgery. | Comparison of the effects of preoperative melatonin or vitamin C administration on postoperative analgesia.cited 19× |
| melatonin and amitriptyline | Decreases - reduced pain | pain | Human | adults with fibromyalgia | Not specified. | Combination pharmacotherapy for the treatment of fibromyalgia in adults.cited 63× |
| 20 mg melatonin as an adjuvant therapy | No effect - showed to be non-significant statistically as well as clinically | endometriosis-associated pain | Human | women with endometriosis-associated pain | 20 mg orally daily | Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain-A randomized double-blinded, placebo-controlled trial.cited 9× |
| 20 mg of melatonin given orally at bedtime | No effect - could not show that ... had better analgesic effect | endometriosis-associated pain | Human | women with endometriosis-associated pain | 20 mg orally daily | Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain-A randomized double-blinded, placebo-controlled trial.cited 9× |
| modified-release melatonin as Circadin™ | Decreases - differences between melatonin and placebo treatment periods after 3 weeks were seen | effect of pain on sleep | Human | patients with severe noncancer chronic pain | 2 mg of Circadin™ before sleep. | Melatonin treatment has consistent but transient beneficial effects on sleep measures and pain in patients with severe chronic pain: the DREAM-CP randomised controlled trial.cited 4× |
| modified-release melatonin as Circadin™ | Decreases - improved | pain intensity scores | Human | patients with severe noncancer chronic pain | 2 mg of Circadin™ before sleep. | Melatonin treatment has consistent but transient beneficial effects on sleep measures and pain in patients with severe chronic pain: the DREAM-CP randomised controlled trial.cited 4× |
| melatonin type 2 receptor agonist IIK-7 | Decreases - attenuates | neuropathic pain | AnimalMolecular | — | — | Melatonin MT2 receptor agonist IIK-7 produces antinociception by modulation of ROS and suppression of spinal microglial activation in neuropathic pain rats. |
| omeprazole 20 mg/d plus sublingual melatonin (3 mg/d) | Decreases - declined significantly | epigastric pain | Human | patients with gastro gastroesophageal reflux disease | 3 mg/day sublingual melatonin + 20 mg/day omeprazole. | Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial.cited 1× |
| melatonin treatment | Decreases - prevents development | neuropathic pain | Animal | rats | — | Melatonin reduces neuropathic pain behavior and glial activation through MT |
| oral melatonin | Decreases - is an effective line of treatment in relieving | epigastric pain and heartburn | Human | — | Not specified | The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease.cited 33× |
| Oral melatonin (10 mg) | No effect - showed no significant difference regarding | occurrence of pain | Human | critically ill patients | 10 mg orally per night. | The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial.cited 53× |
| daily combination of 1200 mg of palmitoylethanolamide and 0.2 mg of melatonin | Decreases - demonstrate the efficacy | pain | Human | fibromyalgia patients | 1200 mg palmitoylethanolamide and 0.2 mg melatonin daily. | A Fixed Combination of Palmitoylethanolamide and Melatonin (PEATONIDE) for the Management of Pain, Sleep, and Disability in Patients with Fibromyalgia: A Pilot Study.cited 1× |
| Melatonin combined with Lactobacillus Rhamnosus GG | No effect - can be considered a therapeutic option | functional abdominal pain disorders | Human | children | — | Randomised controlled trial of melatonin for paediatric functional abdominal pain disorders.cited 3× |
| Melatonin combined with Lactobacillus Rhamnosus GG | Decreases - reduced | mean abdominal pain index (API) | Human | paediatric patients with functional abdominal pain disorders | — | Randomised controlled trial of melatonin for paediatric functional abdominal pain disorders.cited 3× |
| melatonin supplementation (3 mg/night for 12 weeks) | Decreases - decreased | Neuropathic Pain Questionnaire 4 (DN4) scores | Human | persons with multiple sclerosis (PwMS) | 3 mg/night | 12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trial.cited 3× |
| melatonin supplementation | No effect - did not affect | pain measured by the Visual Analog Scale (VAS) | Human | orthopedic trauma patients | — | Effectiveness of melatonin treatment for sleep disturbance in orthopaedic trauma patients: A prospective, randomized control trial.cited 3× |
| oral melatonin (as Circadin) 2 mg at night | No effect - investigate the effects | pain intensity | Human | adults with severe non-malignant pain of at least 3 months' duration | 2 mg daily (as modified-release Circadin) | Phase II double-blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP): a study protocol.cited 3× |
| melatonin receptors (MT1, MT2, MT3) | No effect - involvement in the regulation of | GI motility, inflammation and pain | Human | — | Not specified | Distribution, function and physiological role of melatonin in the lower gut. |
| melatonin receptors (MT1, MT2, MT3) | No effect - involvement in the regulation of | GI motility, inflammation and pain | Human | — | Not specified | Distribution, function and physiological role of melatonin in the lower gut. |
| sublingual melatonin | Increases - significant association between the serum melatonin concentrations and changes | heat pain threshold (HPT) | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| sublingual melatonin | Increases - significant association between the serum melatonin concentrations and changes | heat pain tolerance (HPTo) | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| sublingual melatonin | Increases - significant differences between the placebo vs. the intermediate (0.15 mg/kg) and the highest (0.25 mg/kg) melatonin doses | pain threshold | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| sublingual melatonin | Increases - correlation between the plasma melatonin drug concentration and acute changes | pain threshold | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| sublingual melatonin | Increases - significant association between the serum melatonin concentrations and changes | pressure pain threshold (PPT) | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| sublingual melatonin | Increases - significant association between the serum melatonin concentrations and changes | pressure pain tolerance (PPTo) | Human | healthy subjects aged 19 to 47 y | 0.05 mg/kg, 0.15 mg/kg, and 0.25 mg/kg sublingual melatonin (single dose). | A Phase II, Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of the Melatonin Effect on the Pain Threshold of Healthy Subjects.cited 25× |
| low-dose melatonin | Increases - was associated with | 2-hour pain-freedom rate | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| low-dose melatonin | Increases - was associated with | 2-hour pain-relief rate | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| low-dose melatonin | Decreases - was associated with pain reduction | pain intensity | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| high-dose melatonin | Increases - was associated with | 2-hour pain-freedom rate | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| high-dose melatonin | Increases - was associated with | 2-hour pain-relief rate | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| high-dose melatonin | Decreases - was associated with pain reduction | pain intensity | Human | children and adolescents aged 4-17 years with episodic migraine | <40 kg: 4 mg (high dose) vs. 1 mg (low dose); ≥40 kg: 8 mg (high dose) vs. 2 mg (low dose). | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.cited 19× |
| melatonin intervention | No effect - shows no substantial impact | pain scores after 1 hour | Human | patients after laparoscopic cholecystectomy | Not specified in the abstract. | The Influence of Melatonin on Sleep Quality After Laparoscopic Cholecystectomy: A Meta-Analysis of Randomized Controlled Trials.cited 7× |
| melatonin intervention | No effect - shows no substantial impact | pain scores after 3 hours | Human | patients after laparoscopic cholecystectomy | Not specified in the abstract. | The Influence of Melatonin on Sleep Quality After Laparoscopic Cholecystectomy: A Meta-Analysis of Randomized Controlled Trials.cited 7× |
| natural compound, composed of melatonin (1,5 mg) and cannabis extracts (2.5 mg CBD) | Decreases - evidenced reduction | pain | Human | patients with sleep disorders | 1.5 mg melatonin and 2.5 mg CBD (20 drops sublingually overnight). | Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts.cited 3× |
| oral melatonin premedication | Decreases - significantly reduced | pain levels | Human | children under 3 years having blood samples taken | 0.5 mg/kg body weight (maximum 5 mg), administered orally 30 minutes before the procedure. | POTENTIAL USE OF MELATONIN IN PROCEDURAL ANXIETY AND PAIN IN CHILDREN UNDERGOING BLOOD WITHDRAWAL.cited 25× |
| oral melatonin premedication | Decreases - significantly reduced | pain levels | Human | children over 3 years having blood samples taken | 0.5 mg/kg body weight (maximum 5 mg), administered orally 30 minutes before the procedure. | POTENTIAL USE OF MELATONIN IN PROCEDURAL ANXIETY AND PAIN IN CHILDREN UNDERGOING BLOOD WITHDRAWAL.cited 25× |
| melatonin for migraine | Decreases - reduced | number of days with pain | Human | 351 participants | Not specified | Melatonin for preventing primary headache: A systematic review.cited 13× |
| peroxisome proliferator activated receptors-γ ligands, antiangiogenic agents, and melatonin | Decreases - proven to be efficacious | endometriosis associated pain | Human | animal models | Not available. | Medical treatments for endometriosis-associated pelvic pain.cited 55× |